Human Biotech Animal Health Partnering 2018
Human Biotech Animal Health Partnering
12-13 March, 2018
Boston, USA

Innovating veterinary health with human biotechnology

Why Attend

Join the first ever conference connecting human biotechs with the animal health industry.

Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.

Benefits of the Animal Health industry to Biotechs:

1st
conference of its kind
100+
Attendees
20+
1-to-1 Meetings per person

Testimonials

"This was an excellent event. As a newbie to animal health this was an eye opener. Some great connections and introductions. I would highly recommend your conference. The right balance of networking and information. Thank you!"

Sean Ekins, CEO, COLLABORATIONS PHARMA

 

"This conference provided relevant information and has led to a potential collaboration. I thought the conference was well focused. It was time well spent. I learned a lot and had productive networking sessions. The concept of the confluence of Human Biomedical development and Animal health is integral to our business plan. Kalos looks to leverage its proof of concept work as well as safety and tox to create parallel product lines."

George Colberg, CEO, Kalos Therapeutics, Inc.

 

"A well organized conference that established a strong link between biotechnology innovation and potential veterinary uses.”

Michael G. Palfreyman, Director, R&D Advisory Board, PAFOS PHARMA LLC

WHO SHOULD ATTEND?

HUMAN BIOTECHNOLOGY

Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:

 

ANIMAL HEALTH

-  Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies
-  Market Intelligence and Consultancy Providers

 

INVESTMENT & SERVICE PROVIDERS

-  Private Equity & Venture Capital Investors
-  Investment Bankers & M&A advisors
-  Legal Advisory

Attendees at Boston 2018

Sample attendees from Human Biotech & Animal Health Boston 2018

Benefits of Attending

 

  1. Explore opportunities for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships.
  2. Forge relationships with animal health executives in pre-scheduled 1-on-1 meetings, and discuss research collaborations, deal-licensing and other business development opportunities.
  3. Discuss unmet medical needs in veterinary health, and learn how the regulatory road works, how the industry operates and which technologies are of interest to animal pharmaceutical and nutrition companies.
  4. Identify commercial potential in your translational technologies with investors and advisory firms specializing in the veterinary health industry.

Highlights from Boston 2018

Human Biotech & Animal Health, Boston 2018

The Speakers

 

Heather Wasserman

Senior Director
Eli Lilly and Company

Heather Wasserman

Senior Director
Eli Lilly and Company

Heather Wasserman

Senior Director
Eli Lilly and Company
 

Scott Brown

Independent Animal Health Expert

Scott Brown

Independent Animal Health Expert

Scott Brown

Independent Animal Health Expert
 

Christine Adreani

Director, Translation In Vivo Models Global Research Platform
Sanofi Genzyme

Christine Adreani

Director, Translation In Vivo Models Global Research Platform
Sanofi Genzyme

Christine Adreani

Director, Translation In Vivo Models Global Research Platform
Sanofi Genzyme
 

Atsushi Nagahisa

Founder & Innovation Advisor
RaQualia Pharma Inc.

Atsushi Nagahisa, Ph.D., is President of DNA Partners LLC.  Prior to forming DNA Partners, Dr. Nagahisa served on the Board of Directors of RaQualia Pharma Inc. (RaQualia), a biopharmaceutical venture he founded in 2008.  He served as Representative Director, President and CEO of RaQualia from its inception through August 2012.  Dr.

Atsushi Nagahisa

Founder & Innovation Advisor
RaQualia Pharma Inc.

Atsushi Nagahisa

Founder & Innovation Advisor
RaQualia Pharma Inc.

Atsushi Nagahisa, Ph.D., is President of DNA Partners LLC.  Prior to forming DNA Partners, Dr. Nagahisa served on the Board of Directors of RaQualia Pharma Inc. (RaQualia), a biopharmaceutical venture he founded in 2008.  He served as Representative Director, President and CEO of RaQualia from its inception through August 2012.  Dr. Nagahisa raised $111 million to launch RaQualia, the first, organic spin-out in Pfizer’s history, and then in July 2011 successfully raised an additional $83 million in a public offering (IPO) on the Osaka Securities Exchange JASDAQ Growth Market.  Under his leadership, RaQualia established over 300 collaborations and partnerships with institutions and corporations in 17 countries around the world.  Galliprant® (grapiprant tablets) and ENTYCE® (capromorelin oral solution), approved by the U.S. Food and Drug Administration in March 2016 and May 2016, respectively, were the result of licensing deals completed between RaQualia and Aratana Therapeutics, Inc. in December 2010.

 

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago.

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993, initially focusing on the clinical translation of existing gene transfer technologies but soon redirecting his efforts to the development of second and third generation gene transfer platforms, the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.

More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Throughout his career, the focus of Dr. Wilson's research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders. He is the founder of a 501(c)3 called Health Through Fitness in Orphan Diseases and Director of a bicycle team called Rare Disease Cycling whose participants compete at a national level and help raise money for rare disease research.

Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in peer-reviewed literature and is an inventor on over 117 patents. He was the second President of the American Society of Gene Therapy, the 2014 recipient of the William Osler Patient Oriented Research Award of the University of Pennsylvania and 2015 recipient of the Scientific Achievement Award

 

Steven St. Peter

Founder & CEO
Aratana Therapeutics

Steven St. Peter, M.D. is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries.

Steven St. Peter

Founder & CEO
Aratana Therapeutics

Steven St. Peter

Founder & CEO
Aratana Therapeutics

Steven St. Peter, M.D. is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries. He has previous investment experience from Apax Partners and The Carlyle Group, two private equity firms. Dr. St. Peter was previously an Assistant Clinical Professor of medicine at Columbia University. He received his M.D. from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. Prior to his medical training, he was an investment banker at Merrill Lynch. Dr. St. Peter also holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. Dr. St. Peter has served as a director of PharmAthene, Inc., a publicly-traded biodefense company, since August 2007 and is currently a member of its governance and nominating committee. Dr. St. Peter has also served as a member of the Board of Directors of the Kansas City Area Life Sciences Institute since March 2014 and as a member of the Board of Directors of the Greater Kansas City Foundation since November 2015. Dr. St. Peter’s previous board experience includes MPM Acquisition Corp., Proteon Therapeutics, Inc., Rhythm Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc.

 

Stephen Martin

Head of Global Pharmaceutical R&D
Boehringer Ingelheim Animal Health

As Head of Global Pharmaceutical R&D at Boehringer Ingelheim Animal Health Stephen Martin has:

Stephen Martin

Head of Global Pharmaceutical R&D
Boehringer Ingelheim Animal Health

Stephen Martin

Head of Global Pharmaceutical R&D
Boehringer Ingelheim Animal Health

As Head of Global Pharmaceutical R&D at Boehringer Ingelheim Animal Health Stephen Martin has:

- Lead functions responsible for discovering, developing, and gaining world-wide marketing authorizations for animal health medicines and health products.
- Lead the global R&D functions that support manufacturing of pharmaceutical drugs. Includes functions responsible for analytical methods, formulation, technical transfer and investigations for development and commercial products.
- Implemented and lead a team and process for collaborating with human pharma and biopharma to identify, transfer and develop human medicines for veterinary use.
- Increased pipeline value by over 50%, and number of projects and project
progression by 300%, with a neutral headcount target.
- Site leader for a GXP R&D facility (90,000 square feet)
- Member of the R&D Leadership Team and the BI Extended Leadership Team with responsibility for the execution of R&D and business strategy.

 

Kristin Bloink

Vice President of Regulatory Affairs and Pharmacovigilance
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Vice President of Regulatory Affairs and Pharmacovigilance
Elanco

Kristin Bloink

Vice President of Regulatory Affairs and Pharmacovigilance
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis.

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis. At Eli Lilly/Elanco, she now directs companion animal studies across institutions in order to leverage high quality, systematic translational data with the goal of improving both human and animal health.

 

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry.

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses.  He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs.  Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.

 

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

 

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis.

Ailis Tweed-Kent

CEO
Cocoon Biotech

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as PEPFAR/Office of U.S. Global AIDS Coordinator, London School of Hygiene & Tropical Medicine, and the Global Health Delivery Project. She brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame.

 

Brian Kopp

Partner
Stonehaven Consulting

Brian Kopp is a Partner at Stonehaven Consulting AG.  He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors.  Since 2007, Brian has served as CFO and V.P.

Brian Kopp

Partner
Stonehaven Consulting

Brian Kopp

Partner
Stonehaven Consulting

Brian Kopp is a Partner at Stonehaven Consulting AG.  He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors.  Since 2007, Brian has served as CFO and V.P. of Operations and Strategy with Elanco Animal Health, a division of Eli Lilly and Company.  Over this period, Elanco has grown Revenues from $700 million to over $3 billion, emerged as a top tier player in the industry, achieved top tier Operating margins, experienced significant expansion of business lines, global capabilities, and overall value.  This significant growth was achieved by executing on an aggressive transformation agenda that included capitalizing on a mix of organic and inorganic opportunities.  After 27 years working in increasingly relevant roles within Corporate settings, Brian is excited by the opportunity to take his experiences and insights and help Animal Health partners develop and/or realize their strategic goals.   

 

Sean Ekins

CEO
Collaborations Pharma

Sean Ekins

CEO
Collaborations Pharma

Sean Ekins

CEO
Collaborations Pharma

Headline Partner

Associate Partners

Event Partners

Networking Reception Host

Marketing Partners

The Agenda

 

Download Full Agenda

Venue

Hilton Boston Dedham Hotel, 25 Allied Dr., Dedham, MA 02026, USA

Hilton Hotel image, Human Biotech & Animal Health Congress

Overlooking tranquil woods, and only 10 miles from downtown Boston, this year we've chosen the newly-renovated Hilton Boston/Dedham as our venue of choice.

Located off I-95, it is within close proximity to multiple train stations and there is a complimentary shuttle service allowing you to travel around easily.

Inside the hotel you’ll find modern and welcoming rooms and suites, great recreational amenities, vibrant local cuisine and stunning indoor/outdoor spaces.

Unfortunately the disocunted room rate for the event has now expired but you can still book at the Hilton Dedham Hotel at very reasonable prices.


Book here

T: +1-781-329-7900

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

Book a Team to Save More!

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Animal Health Investment Europe:

  • Please note that a $79 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Those offering consultancy or market intelligence services do not qualify for the Start-Up rate.
  • PLEASE NOTE – no additional discounts are available on ‘Start-up Company’ pricing. Group discounts are ONLY available on ‘Delegate’ pricing.
  • You can view our Cancellation Policy here.

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.

CONTACT US TO FIND OUT MORE

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.